Amarantus Bioscience - AMBS
The company's patented MANF technology could lead to a cure to a myriad of diseases including Parkinson's Disease and Alzheimer's Disease.
"Big phare" development partnership or buyout is realistic.
Buy a few shares before the company's conference call on April 17.
Most undervalued bio=tech in the market.
Potential for a joint venture or "big pharma" partnership.
Read today's Yahoo news regarding the company's MANF study data.
Get in today under a dime.